NEW YORK (360Dx) – Becton Dickinson announced this week an early access program for its BD Resolve single-cell gene expression platform that captures and analyzes "hundreds to tens of thousands of individual cells in a broad range of sizes and types."

The platform includes reagents that can analyze the whole transcriptome and targeted or custom-designed gene-specific panels, BD said, and noted that it's possible to improve data accuracy and reduce sequencing costs by pairing the platform with the firm's Facsmelody flow cytometer for cell sorting and enrichment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.